Clinical trials: Systemic Autoimmune Disease
Lupus Erythematosus, Systemic, Scleroderma, Systemic
The Impact of Illness Perceptions on Health Related Outcomes in Patients With Lupus and Systemic Sclerosis
This research project has the overall objective to investigate the direction of the associations between illness perceptions, their influencing factors and health-related outcomes.
- Trial name
- NCT02655640
- Testing
- Questionnaires
- Volunteers
- 241 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Systemic Lupus, Skin Lupus
Lupus and Observance
A poor therapeutic observance is described between 3 and 76% cases in systemic lupus. It is associated with an increased risk of relapses, hospitalizations, morbidity and poor renal prognosis.
- Trial name
- LUPOBS (NCT03019926)
- Testing
- Hydroxychloroquine dosage
- Where
- France
- Volunteers
- 200 people
- Sponsor
- University Hospital Center of Martinique
Lupus Nephritis
Anti-alpha-actinin Antibodies and Lupus Nephritis Activity
Lupus nephritis (LN) develops in 30-60% of systemic lupus erythematosus (SLE) patients and remains a leading cause of morbidity, with 10-30% progressing to end-stage renal disease within 15 years.
- Trial name
- NCT07505576
- Testing
- renal biopsy, serum anti-alpha-actinin antibodies, CBC, serum creatinine and urea, estimated GFR, ESR, CRP, urine analysis, ANA, anti dsDNA, C3 & C4, serum albumin, 24-hrs urinary protein, and U. ACR
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Assiut University
Lupus Nephritis
Assess the Efficacy and Safety of Multi-target Therapy in Lupus Nephritis
The purpose of this study is to assess the efficacy and safety of multi-target therapy in the treatment of class Ⅲ,Ⅳ,Ⅴ,Ⅲ+Ⅴand Ⅳ+Ⅴ lupus nephritis.
- Trial name
- NCT00876616
- Testing
- Tacrolimus+Mycophenolate mofetil, Cyclophosphamide
- Where
- China
- Volunteers
- 362 people
- Sponsor
- Zhi-Hong Liu, M.D.
Systemic Lupus Erythematosus, Cardiovascular Disease
The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVD
Background: People with systemic lupus erythematosus (SLE) are at risk of developing complications in their blood vessels. This can increase the risk of heart attacks or stroke.
- Conditions
- Systemic Lupus Erythematosus, Cardiovascular Disease, Premature Atherosclerosis
- Trial name
- NCT05440422
- Testing
- anifrolumab
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Systemic Lupus Erythematosus (SLE), Sjogren's Syndrome
Anti-CD19-CD3E-CAR-T Cells in Relapsed/Refractory Autoimmune Disease
This is an investigator-initiated trial to evaluate the safety and efficacy of anti-CD19-CD3E-CAR-T cells in the relapse or refractory autoimmune diseases.
- Conditions
- Systemic Lupus Erythematosus (SLE), Sjogren's Syndrome, Systemic Sclerosis, Inflammatory Myopathy
- Trial name
- NCT06373081
- Testing
- Anti-CD19-CD3E-CAR-T cells
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Shanghai Changzheng Hospital
Multiple Sclerosis
Mesenchymal Cells From Autologous Bone Marrow, Administered Intravenously in Patients Diagnosed With Multiple Sclerosis
This is a phase I / II for the evaluation of the safety and feasibility of intravenous infusion of mesenchymal cells from autologous bone marrow in patients with Multiple Sclerosis.
- Trial name
- NCT01745783
- Testing
- Bone marrow mesenchymal stem cells autologous
- Where
- 3 sites in Spain
- Volunteers
- 26 people
- Sponsor
- Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud
Lupus Nephritis
Efficiency of Use of Baracetinib in Treatment of Lupus Nephritis
Patients with systemic lupus erythematosus have substantial unmet medical need. Baricitinib is an oral selective Janus kinase (JAK)1 and JAK2 inhibitor that we hypothesised might have therapeutic benefit in patients with systemic…
- Trial name
- NCT05432531
- Testing
- Anti JAK1,2, Cyclophosphamid
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Assiut University
Systemic Lupus Erythematosus (SLE), Juvenile SLE
Relevance of Monitoring Blood and Salivar Levels of Drugs Used in Rheumatic Autoimmune Diseases
No drug treatment is completely free of risk and lack of response, adverse events and poor adherence may affect its effectiveness.
- Conditions
- Systemic Lupus Erythematosus (SLE), Juvenile SLE, Cutaneous Lupus
- Trial name
- NCT03122431
- Testing
- Thalidomide, Hydroxychloroquine reduced, standard dose of HCQ
- Where
- Brazil
- Volunteers
- 93 people
- Sponsor
- University of Sao Paulo General Hospital
Systemic Lupus Erythematosus, Scleroderma
Efficacy and Safety of HN2301 in Autoimmune Diseases（AIDs）
This is an open lable and single arm study, is designed to evaluate the safety and preliminary efficacy of HN2301 in Autoimmune Disease（AID）
- Conditions
- Systemic Lupus Erythematosus, Scleroderma, Rheumatoid Arthritis
- Trial name
- SLE，SSc，RA (NCT06801119)
- Testing
- HN2301 injection
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shenzhen MagicRNA Biotechnology Co., Ltd
Systemic Sclerosis, Gougerot Sjogren Syndrome
Echo Systemic Sclerosis
Systemic sclerosis is an autoimmune connective tissue disease with undefined etiology and characterized by progressive fibrosis of the skin and major organs.
- Conditions
- Systemic Sclerosis, Gougerot Sjogren Syndrome, Sicca-Asthenia-Polyalgia Syndrome
- Trial name
- NCT03143413
- Testing
- Ultrasonography
- Where
- France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Clermont-Ferrand
Rheumatic Joint Disease
Observational Study of Pediatric Rheumatic Diseases: The CARRA Registry
Continuation of the CARRA Registry as described in the protocol will support data collection on patients with pediatric-onset rheumatic diseases. The CARRA Registry will form the basis for future CARRA studies.
- Trial name
- NCT02418442
- Where
- 82 sites in United States, Canada and 3 more
- Volunteers
- 20,000 people
- Sponsor
- Duke University
Systemic Lupus Erythematosus, Systemic Scleroderma
Characterization of Autoreactive b Lymphocytes in Autoimmune Diseases and Immune Deficiencies
Autoimmune diseases (AID), whether systemic or organ-specific, affect approximately one in ten people, and their prevalence continues to increase.
- Conditions
- Systemic Lupus Erythematosus, Systemic Scleroderma, ANCA-associated Vasculitis, Antiphospholipid Syndrome
- Trial name
- AutoB-Tetramer (NCT07251179)
- Testing
- blood draw
- Where
- France
- Volunteers
- 200 people
- Sponsor
- University Hospital, Strasbourg, France
Systemic Lupus Erythematosus, Lupus Nephritis
Epigenetics in Lupus Nephritis
This is a translational study for the identification of epigenetic changes detectable in sera of patients suffering from Systemic Lupus erythematosus.
- Trial name
- Epi_LN (NCT04648059)
- Testing
- Blood sampling
- Where
- Germany
- Volunteers
- 60 people
- Sponsor
- University of Göttingen
Auto Immune Disease, Auto-inflammatory Disease
Effect of a Weekly Yoga Program Integrated Into Standard Care on Disease Activity, Fatigue, Mood, and Treatment Adherence in Patients With Systemic Autoimmune and Inflammatory Diseases: A Prospective Observational Study
"Systemic autoimmune and inflammatory diseases (SAIDs) are chronic disorders associated with substantial impairment in quality of life, largely due to persistent fatigue, chronic pain, and mood disorders.
- Trial name
- YOGAMID (NCT07685288)
- Testing
- yoga program
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Lupus Nephritis
Zanubrutinib in Participants With Active Proliferative Lupus Nephritis
The primary objective of this study is to evaluate the efficacy of zanubrutinib added to standard of care as measured by complete renal response for participants with active proliferative lupus nephritis
- Trial name
- NCT04643470
- Testing
- Zanubrutinib
- Where
- 44 sites in China
- Volunteers
- 177 people
- Sponsor
- BeiGene
Lupus Nephritis
Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of Ixazomib in Lupus Nephritis (LN)
The purpose of this study is to characterize the safety and tolerability of ixazomib when administered as multiple oral doses at escalating dose levels in participants with lupus nephritis.
- Trial name
- NCT02176486
- Testing
- Ixazomib
- Where
- 35 sites in United States, France and 5 more
- Volunteers
- 12 people
- Sponsor
- Takeda
Lupus Nephritis
Fixed-dose Versus Concentration-controlled Mycophenolate Mofetil for the Treatment of Active Lupus Nephritis
A randomized open-label study of fixed-dose versus concentration-controlled mycophenolate mofetil for treatment of active lupus nephritis.
- Trial name
- NCT03920059
- Testing
- Mycophenolate Mofetil
- Where
- Thailand
- Volunteers
- 2 people
- Sponsor
- Chulalongkorn University
Systemic Lupus Erythematosus
The Effect of Metformin on Reducing Lupus Flares
This is a multicenter, randomised, double-blind placebo controlled trial on the efficacy and safety of add-on metformin to conventional immunosuppressants in systemic lupus erythematosus (SLE).
- Trial name
- Met Lupus (NCT02741960)
- Testing
- metformin
- Where
- China
- Volunteers
- 180 people
- Sponsor
- RenJi Hospital
Granulomatosis With Polyangiitis, Microscopic Polyangiitis
Comparison Study of Two Rituximab Regimens in the Remission of ANCA Associated Vasculitis
The aim of this study is to assess the efficacy of a rituximab regimen based on rate of ANCA and CD19 lymphocytes for maintenance treatment in systemic ANCA-associated vasculitis: prospective, multicenter, controlled, randomized…
- Conditions
- Granulomatosis With Polyangiitis, Microscopic Polyangiitis, Renal Limited Forms
- Trial name
- MAINRITSAN 2 (NCT01731561)
- Testing
- Rituximab (Arm B), Rituximab (Arm A)
- Where
- France
- Volunteers
- 166 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris